US research roundup: Allstate, Caribou Biosciences, Zscaler
ZS•Analysts revised ratings and price targets on several U.S.-listed companies. HSBC raised Allstate to buy from hold, RBC cut Caribou Biosciences to sector perform from outperform, and Jefferies raised Zscaler’s target to $250 from $220.
1. Selected analyst actions
HSBC raised its rating on Allstate to buy from hold while cutting its target price to $266 from $282. RBC cut Caribou Biosciences to sector perform from outperform and lowered its target to $1 from $10.
2. Zscaler targets raised
Jefferies raised its Zscaler target price to $250 from $220. Other analysts also raised targets, including Wells Fargo to $260 from $215 and Stephens to $265 from $225.
